治疗前淋巴细胞与单核细胞比值可预测 TAS-102 和贝伐珠单抗治疗转移性结直肠癌的疗效。
The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab.
机构信息
Department of Chemotherapy, Tokyo Women's Medical University, Yachiyo Medical Center, Yachiyo, Japan.
Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan;
出版信息
Anticancer Res. 2021 Jun;41(6):3131-3137. doi: 10.21873/anticanres.15098.
BACKGROUND/AIM: Our multicenter phase II TAS-CC3 study demonstrated favorable median progression-free survival (PFS) and overall survival (OS) of 32 metastatic colorectal cancer (mCRC) patients treated with TAS-102 + bevacizumab as 3-line treatment.
PATIENTS AND METHODS
We investigated the predictive and prognostic values of pre-treatment blood inflammation-based scores, including the neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte ratio (LMR) on disease-control (DC), PFS and OS by a post-hoc analysis.
RESULTS
Receiver operating characteristic curve analyses of the 3 inflammation-based scores versus DC showed the best predictive performance for LMR, followed by NLR and PLR. The high-LMR group had a significantly higher DC rate than the low group (87.5 vs. 43.8%). The high-LMR group showed significantly longer survival than the low group (4.9 vs. 2.3 m for median PFS) (21.0 vs. 6.1 m for median OS).
CONCLUSION
The pre-treatment LMR is a valid predictive and prognostic biomarker for mCRC patients undergoing TAS-102 and bevacizumab treatment.
背景/目的：我们的多中心 II 期 TAS-CC3 研究表明，32 名转移性结直肠癌（mCRC）患者接受 TAS-102 +贝伐珠单抗作为三线治疗，中位无进展生存期（PFS）和总生存期（OS）均有较好的获益。
患者和方法
我们通过回顾性分析，研究了治疗前血液炎症指标（包括中性粒细胞与淋巴细胞比值[NLR]、血小板与淋巴细胞比值[PLR]和淋巴细胞与单核细胞比值[LMR]）对疾病控制（DC）、PFS 和 OS 的预测和预后价值。
结果
3 种炎症指标与 DC 的受试者工作特征曲线分析显示，LMR 的预测性能最佳，其次是 NLR 和 PLR。高 LMR 组的 DC 率显著高于低 LMR 组（87.5%比 43.8%）。高 LMR 组的生存时间明显长于低 LMR 组（中位 PFS 分别为 4.9 个月和 2.3 个月）（中位 OS 分别为 21.0 个月和 6.1 个月）。
结论
治疗前 LMR 是接受 TAS-102 和贝伐珠单抗治疗的 mCRC 患者的有效预测和预后生物标志物。
Zotero 插件